Lai Vivien Wai Yun, Chen Gang, Sinclair Rodney
Faculty of Medicine, Nursing and Health Sciences, Monash School of Medicine, Monash University, Clayton, Australia.
Centre for Health Economics, Monash Business School, Monash University, Clayton, Australia.
J Dermatolog Treat. 2021 Mar;32(2):250-257. doi: 10.1080/09546634.2019.1654068. Epub 2019 Aug 20.
Alopecia areata (AA) is a disfiguring disease with substantial psychological burden. No studies explore the efficacy of pharmacotherapy through health-related quality of life (HRQoL) using both disease-specific and generic quality of life (QoL) instruments. We present the first study to elicit health utility from patients with AA and to evaluate the efficacy of cyclosporin in relation to HRQoL using both measures.
Participants with moderate to severe AA from a placebo-controlled randomized trial investigating cyclosporin were administered the generic preference-based HRQoL instrument, Assessment of Quality of Life-8D (AQoL-8D) and the disease-specific HRQoL instrument, Alopecia Areata Symptom Impact Scale (AASIS). HRQoL was measured at each study visit and compared to baseline.
A number of 32 participants were analyzed. The mean health utility was 0.748. At 3 months, the cyclosporin group had trends for greater improvement in HRQoL across 6 of 8 AQoL-8D dimensions and 5 of 7 AASIS symptom domains compared to placebo. HRQoL was lower than Australian population norms across 6 of 8 AQoL-8D dimensions.
Patients with AA had a mean health utility of 0.748. Treatment with cyclosporin 4 mg/kg/d for 3 months resulted in trends for improvement of HRQoL across multiple dimensions in both disease-specific and generic measures. Capsule summary The mean health utility for patients with AA was 0.748. Patients with alopecia areata have impaired health-related quality of life across 6 of 8 AQoL-8D dimensions compared to population norms. Treatment with oral cyclosporin for moderate to severe AA resulted in trends for improvement in QoL across multiple dimensions.
斑秃（AA）是一种有损容貌的疾病，会带来沉重的心理负担。尚无研究使用疾病特异性和通用生活质量（QoL）工具，通过健康相关生活质量（HRQoL）来探究药物治疗的疗效。我们开展了第一项研究，以获取斑秃患者的健康效用值，并使用这两种测量方法评估环孢素相对于HRQoL的疗效。
来自一项研究环孢素的安慰剂对照随机试验中的中重度斑秃参与者，接受了基于偏好的通用HRQoL工具——生活质量评估-8维度（AQoL-8D）和疾病特异性HRQoL工具——斑秃症状影响量表（AASIS）的评估。在每次研究访视时测量HRQoL，并与基线进行比较。
分析了32名参与者。平均健康效用值为0.748。在3个月时，与安慰剂相比，环孢素组在AQoL-8D的8个维度中的6个维度以及AASIS的7个症状领域中的5个领域，HRQoL有更大改善的趋势。在AQoL-8D的8个维度中的6个维度上，HRQoL低于澳大利亚人群规范。
斑秃患者的平均健康效用值为0.748。以4mg/kg/d的剂量服用环孢素3个月的治疗，在疾病特异性和通用测量方法的多个维度上均有改善HRQoL的趋势。总结：斑秃患者平均健康效用值为0.748。与人群规范相比，斑秃患者在AQoL-8D的8个维度中的6个维度上，健康相关生活质量受损。口服环孢素治疗中重度斑秃导致多个维度的QoL有改善趋势。
